These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20216234)

  • 1. Fatal neurotoxicity in a patient with down syndrome treated with chemotherapy, irradiation, stem cell transplant, and clofarabine.
    Johnston DL; Bains T; Mandel K; Klaassen R; Halton J
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):e111-3. PubMed ID: 20216234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia.
    Baytan B; Ozdemir O; Gunes AM; Dönmez O
    J Pediatr Hematol Oncol; 2010 Mar; 32(2):144-6. PubMed ID: 20057324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatal palmar-plantar erythrodysesthesia after clofarabine and cytarabine chemotherapy.
    Hwang YY; Trendell-Smith NJ; Yeung CK; Kwong YL
    Acta Haematol; 2012; 128(3):151-3. PubMed ID: 22890199
    [No Abstract]   [Full Text] [Related]  

  • 4. A Case of Subacute Encephalopathy Developing After Treatment With Clofarabine and Methotrexate That Resolved With Corticosteroids.
    Tzachanis D; Haider M; Papazisis G
    Am J Ther; 2016; 23(3):e937-40. PubMed ID: 24987945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal skin and liver toxicity in a patient treated with clofarabine.
    Johnston DL; Mandel KM
    Pediatr Blood Cancer; 2008 May; 50(5):1082. PubMed ID: 17957757
    [No Abstract]   [Full Text] [Related]  

  • 6. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic effect of clofarabine in children with relapsed or refractory acute lymphoblastic leukemia].
    Suo P; Zhang LP; Wu J; Lu AD; Wang B; Zuo YX; Cheng YF; Liu GL
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):444-7. PubMed ID: 23791059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clofarabine: a new treatment option for patients with acute myeloid leukemia.
    Larson ML; Venugopal P
    Expert Opin Pharmacother; 2009 Jun; 10(8):1353-7. PubMed ID: 19463072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nursing considerations for optimal outpatient management of adult patients with leukemia treated with clofarabine.
    Dressel A; Kwari M; McGreal AM
    Clin J Oncol Nurs; 2011 Feb; 15(1):E13-23. PubMed ID: 21278032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
    J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
    McGregor BA; Brown AW; Osswald MB; Savona MR
    Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clofarabine in pediatric acute leukemia: current findings and issues.
    Hijiya N; Barry E; Arceci RJ
    Pediatr Blood Cancer; 2012 Sep; 59(3):417-22. PubMed ID: 22354543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clofarabine-associated acute kidney injury and proteinuria.
    Kintzel PE; Visser JA; Campbell AD
    Pharmacotherapy; 2011 Sep; 31(9):923. PubMed ID: 21923594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
    Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
    Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia.
    Moreno L; Fernandez-Navarro JM; Del Mar Andres M; Bautista F; Tasso M; Verdeguer A
    J Pediatr Hematol Oncol; 2012 Jan; 34(1):e17-21. PubMed ID: 21716139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clofarabine associated capillary leak syndrome in a child with lymphoma successfully treated with intravenous immunoglobulin.
    Kesik V; Atas E; Korkmazer N; Babacan O
    J Cancer Res Ther; 2015; 11(3):653. PubMed ID: 26458636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.
    Ngo D; Patel S; Kim EJ; Brar R; Koontz MZ
    J Oncol Pharm Pract; 2015 Aug; 21(4):296-300. PubMed ID: 24664478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
    Tran H; Yang D
    Ann Pharmacother; 2012 Jan; 46(1):89-96. PubMed ID: 22170975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
    Lech-Maranda E; Korycka A; Robak T
    Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clofarabine: emerging role in leukemias.
    Sampat K; Kantarjian H; Borthakur G
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1559-64. PubMed ID: 19715446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.